Clinical Trial Update: Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 clinical study evaluating the safety, tolerability, and immunogenicity of the cancer vaccine mRNA-4157, administered alone and in combination, in partic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• mRNA-4157

Snippet

Sponsor: ModernaTX, Inc. | Conditions: Solid Tumors | Phase 1 | Status: ACTIVE_NOT_RECRUITING